ClinicalTrials.gg
CompletedNCT00426972Updated Aug 28, 2009

Trial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor Sites

A Phase 3 interventional study of estradiol (Zesteem) in Burn, Trauma and Varicose Ulcer, sponsored by Renovo. Completed at 30 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2009-08-28.

Sponsored by Renovo · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Burns with a site in Germany — 4 open to participants now, 4 under way, 1 of them phase 3. Burns · Germany.

Planned enrollment
7th of 21
148 · median 80
Started
2007
with 2 others
Phase 3
7 of 27
1 open now
Registered
2nd of 27
by date

Among the 27 studies in Burns with a site in Germany, this one is the 7th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2007, is one of 7 in phase 3, and was the 2nd registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

4 of the 27 studies in Burns with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Burns with a site in Germany, or all of them as a file.
02

Study summary

This trial will assess the effects of Zesteem (estradiol) on the healing of split thickness skin graft donor sites in patients aged 18-85 years.

03

Conditions studied

  • Burn
  • Trauma
  • Varicose Ulcer
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-85 years who have provided written .
  • Patients requiring skin grafting due to burns, trauma or chronic venous ulcers, with a donor site expected to be between 20 and 200 cm2 on a non-articulated area.
  • Female patients of child bearing potential who are using method(s) of acceptable to the Investigator and agree to do so from at least the screening visit until one month after administration of the final study dose.

Exclusion criteria

Exclusion Criteria:

  • Patients with burns involving more than 15% of their total body area.
  • Patients with sepsis, haemodynamic instability requiring pressor support or positive blood microbiology cultures within 48h of surgery.
  • Patients with inhalation injury requiring artificial respiratory assistance.
  • Patients requiring skin grafts following removal of suspicious skin lesions.
  • Patients who have received treatment with systemic during the 30 days prior to surgery.
  • Patients who have received drugs, radiation or chemotherapy during the three months prior to surgery.
  • Patients with a history of in the previous three years.
  • Patients with uncontrolled diabetes or diabetic ulcers.
  • Patients with diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerability or efficacy.
  • Patients who have previously had skin grafts harvested from the area to be studied.
  • Patients with a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
  • Patients with a history of to any of the drugs or surgical dressings to be used in this trial.
  • Patients who are taking, or have taken, any drugs within 3 months prior to the screening visit.
  • Patients undergoing investigations or changes in management for an existing medical condition.
  • Patients who are or who become pregnant up to and including Day 0 or who are lactating.
  • In the opinion of the Investigator, a patient who is not likely to complete the trial for whatever reason.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
148 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Complete wound closure of skin graft donor site.

Secondary outcomes

  1. Adverse events

  2. Skin graft take

07

Study locations

30 sites
  • Universitatsklinikum Aachen Klinik fur Plastiche Chirurgie
    Aachen, 52074, Germany
  • Universitatsklinik fur Plastiche Chirurgie und Schwerbrandverletze
    Bochum, D-44789, Germany
  • Klinik fur Dermatologie und Allergologie, Bochum St Josef Hospital
    Bochum, D-44791, Germany
  • Carl- Thiem- klinikum Cottbus
    Cottbus, 03048, Germany
  • Abteilung fur Plastiche und Handchirurgie
    Erlangen, 12, 91054, Germany
  • Zentrum der Dermatologie und Venerologie, Johann Wolfgang Institut
    Frankfurt, D-D-60590, Germany
  • Universitatsklinikum Freiburg
    Freiburg, D-79106, Germany
  • Klinik fur Plastiche- Hand und Wiederherstellungschirurgie
    Hannover, 30625, Germany
  • Klinik fur Dermatologie, Friedrich-Schiller Universitat Jena
    Jena, 07740, Germany
  • Klinikum Koln-Merheim Abteilung Plastiche-, Rekonstruktive-, Asthetische- Hand- Verbrennungschirurgie
    Koln, 51109, Germany
  • Klinikum St. Georg- Leipzig
    Leipzig, D-04129, Germany
  • Otto-von-Gericke Universitat Magdeburg, universitatsklinikum fur Dermatologie und Venerologie
    Magdeburg, 39120, Germany
  • Klinik fur Plastiche-Asthetische- u. Handchiurgie. Kinikum Offenbach
    Offenbach, D-63069, Germany
  • HSK, Wilhelm Fresenius Klinik
    Wiesbaden, 65191, Germany
  • P Stradins Clinical University Hospital
    Riga, LV1002, Latvia
  • Regional Clinical Hospital, Partizana
    Krasnoyarsk, 660022, Russian Federation
  • City Clinical Hospital # 36
    Moscow, 105187, Russian Federation
  • City Clinical Hospital # 36
    Moscow, 111539, Russian Federation
  • Russian Medical Academy for Postgraduate Education, Surgery
    Moscow, 113093, Russian Federation
  • City Clinical Hospital #13
    Moscow, 115280, Russian Federation
  • The Central Clinical Hospital # 1 of LLC "Russian Railways"
    Moscow, 125367, Russian Federation
  • Research Institute for Traumatology and Orthopaedy, Verhne-Volzhskaya Naberezhnaya
    Novorogod, Russian Federation
  • City Clinical Hospital # 7
    Saratov, 410005, Russian Federation
  • Clinical Hospital n.a. N.V. Solovyov
    Yaroslavl, Russian Federation
  • Stoke Mandeville Hospital
    Aylesbury, Buckinghamshire HP21 8AL, United Kingdom
  • Pinderfields Hospital
    Aberford Road, Wakefield WF1 4DG, United Kingdom
  • McIndoe Burns Unit, Queen Victoria Hospital
    East Grinstead, West Sussex RH19 3DZ, United Kingdom
  • Selly Oak Hospital
    Birmingham, B29 6JD, United Kingdom
  • Broomfield Hospital
    Chelmsford, CM1 7ET, United Kingdom
  • Wythenshawe Hospital
    Manchester, M23 9LT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jul 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2007
First posted
Jan 25, 2007
Start
Jan 2007
Primary completionActual
Jul 2008
CompletionActual
Oct 2008
Last update
Aug 28, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00426972
Lead sponsor
Renovo
First posted
Jan 25, 2007
Start date
Jan 2007
Primary completion
Jul 2008
Completion
Oct 2008
Last update
Aug 28, 2009

Study contacts

Ken Dunn, MD
principal investigator · Wythenshawe Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion